Showing 7 posts of 7 posts found.


J&J announces $5bn share repurchase

December 18, 2018
Manufacturing and Production J&J, JJ, Shares, asbestos, baby powder, reuters, scandal

New Jersey-based pharma firm Johnson & Johnson plans to buy back $5 billion in shares after news agency Reuters released …

J&J shares plummet after asbestos cover up allegations emerge

December 17, 2018
Sales and Marketing J&J, JJ, Johnson & Johnson, asbestos, reuters

Shares in American healthcare firm Johnson & Johnson plummeted on Friday after news agency Reuters reported that the New Jersey-based …

Whistleblower accuses Novartis of paying bribes in Turkey to push sales

April 1, 2016
Business Services, Medical Communications, Sales and Marketing Financial, Novartis, legal, reuters

An anonymous whistleblower has accused Swiss drugmaker Novartis (SIX: NOVN) of paying bribes in Turkey through a consulting firm to …

FDA image

Regulators ‘more efficient at approving drugs’

January 19, 2015
Research and Development, Sales and Marketing EMA, EMA), FDA, Health Canada, PMDA)., Pharmaceutical and Medical Devices Agency, Swissmedic, TGA, approvals, cirs, reuters

Global regulatory bodies have become faster at approving new drug products more quickly and consistently, according to a new analysis …


Reuters chief executive joins Pfizer board

July 2, 2014
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Pfizer, james smith, reuters

Pfizer has appointed the chief executive of information and media giant Thomson Reuters to its board of directors. James Smith …

Bayer image

Bayer to make $14 bn move for Merck unit

May 2, 2014
Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Boehringer, Merck, Novartis, Reckitt Benckiser, claritin, reuters

Bayer is in talks with Merck & Co to buy its consumer business and is willing to pay $14 billion …

research image

Report: ‘R&D isn’t paying’

December 3, 2013
Research and Development, Sales and Marketing Deloitte, R&D, pharma, research and development, reuters

On average, the world’s biggest pharma companies are not getting enough of a return out of their R&D efforts, according …

Latest content